What is the successful prediction rate for this test?

Positive predictive values for our AI-based drug response predictions are 80% or higher.

Other Questions

Back to Help Center

Which cancers can I use ImpriMed for? or What type of cancer does ImpriMed predict?

Currently, our services are for canine lymphoma and leukemia. We will be expanding our services to other species and other blood / lymphoid cancers in the near future.

What type of sample is needed – just aspirates and a typical flow sample?

We need about 10 million cancer cells to run the full chemosensitivity panel so we ask that you conduct an aggressive woodpecker style FNA, poking as many nodes as possible and putting the cells into our proprietary media tubes (ensures we receive live cells), then of course we need a whole blood sample (2mL).

How should I discard the expired media we still have?

The media and tubes can be decontaminated in or with 10% bleach and discarded as normal.

What does PARR tell me about my patient’s specimen?

PARR, which stands for PCR for Antigen Receptor Rearrangements, is used to discriminate between lymphoma/leukemia and reactive/inflammatory conditions when cytology is equivocal. Our canine PARR assay detects the expansion of B-cell cancer clones by amplifying the VJ region of the immunoglobulin heavy chain gene (IgH) and detects the expansion of T-cell cancer clones by amplifying a region in the T-cell receptor gamma chain gene.

Why should I order ImpriMed services?

ImpriMed offers a unique precision oncology service that helps you to find the best anticancer drugs for your patients. ImpriMed directly tests a panel of commonly used anticancer drugs on your patients’ live cells in our A2LA accredited lab. In addition, we continually collect patient outcomes that are updated via regular follow-up with pet parents. As our database grows, so does the performance of our anticancer drug response predictions and your ability to develop a personalized treatment plan for each pet patient. So, when you order an ImpriMed service, you are actively contributing to our dataset and helping to improve cancer care for your patients and the ImpiMed user community.